NasdaqGM - Nasdaq Real Time Price USD
ADMA Biologics, Inc. (ADMA)
8.69 +0.12 (+1.40%)
At close: June 23 at 4:00:00 PM EDT
8.71 +0.02 (+0.23%)
Pre-Market: 6:57:14 AM EDT
Trade ADMA on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreChart Range Bar
Loading chart for ADMA
- Previous Close
8.57 - Open
8.70 - Bid 6.29 x 100
- Ask 10.93 x 100
- Day's Range
8.48 - 8.79 - 52 Week Range
7.21 - 20.46 - Volume
2,889,652 - Avg. Volume
6,757,354 - Market Cap (intraday)
2.014B - Beta (5Y Monthly) 0.73
- PE Ratio (TTM)
12.78 - EPS (TTM)
0.68 - Earnings Date (est.) Aug 5, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.60
Recent News
View More
Performance Overview
Trailing total returns as of 6/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
ADMA
52.36%
S&P 500 (^GSPC)
7.60%
1-Year Return
ADMA
51.37%
S&P 500 (^GSPC)
22.24%
3-Year Return
ADMA
124.55%
S&P 500 (^GSPC)
69.39%
5-Year Return
ADMA
423.49%
S&P 500 (^GSPC)
73.64%
Earnings Trends
View MoreAnalyst Insights
View MoreStatistics
View MoreValuation Measures
As of 6/23/2026
Market Cap
2.01B
Enterprise Value
2.08B
Trailing P/E
12.77
Forward P/E
10.46
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.15
Price/Book (mrq)
5.16
Enterprise Value/Revenue
4.08
Enterprise Value/EBITDA
9.39
Financial Highlights
Profitability and Income Statement
Profit Margin
32.43%
Return on Assets (ttm)
21.99%
Return on Equity (ttm)
43.30%
Revenue (ttm)
509.86M
Net Income Avi to Common (ttm)
165.35M
Diluted EPS (ttm)
0.68
Balance Sheet and Cash Flow
Total Cash (mrq)
55.92B
Total Debt/Equity (mrq)
110.67%
Levered Free Cash Flow (ttm)
58.35M
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
7.20
+4.35%
Mkt Cap 1.243B
Industry Drug Manufacturers—Specialty & Generic
Company Insights
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports
View MoreWhat does Argus have to say about ADMA?
ADMA BIOLOGICS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetRaising target price to $8.00
ADMA BIOLOGICS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $7.00
ADMA BIOLOGICS INC has an Investment Rating of HOLD; a target price of $7.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetWhat does Argus have to say about ADMA?
ADMA BIOLOGICS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target